Zetia Generics - One more drug that needs to be tried and failed before PCSK9s!!

Amgen CV - better hope those outcomes are fantastic or you are still Fucked!

Zetia generics launch sets Merck up for $1.4B hit to 2017 cholesterol sales

Merck & Co.'s big-selling cholesterol-fighter Zetia is at the end of its exclusive road. The $2.5 billion seller now faces its first generic competitor, which threatens not only its own revenue, but the blockbuster sales of its combination-med cousin, Vytorin.

Endo’s Par Pharmaceutical unit on Monday launched Zetia's first copycat—and only copycat for six months under FDA exclusivity rules. Though Merck's Zetia sales are likely to suffer from the get-go, they'll face their biggest declines after that 180-day monopoly lifts next year and multiple generics makers rush in.

The Zetia generics launch as the cholesterol-fighting field grows increasingly crowded, what with the launch of pricey PCSK9 therapies Praluent from Sanofi and Regeneron and Repatha from Amgen. The advent of those drugs, however, could give a boost to ezetimibe versions, however; payers leery of the PCSK9 meds' $14,000-plus list prices are requiring patients to try Zetia as an add-on to statin therapy—or Vytorin—before they'll pay for Praluent or Repatha.